GlassScriptPhysician profile
Kara Oprian Fess
NPI 1700843950
$920.69
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $104 · 2021: $169 · 2022: $222 · 2023: $93.32 · 2024: $70.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $164.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $127.13 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Orexo US, INC. | $111.40 | 2020-2022 | |
| Amgen INC. | $88.17 | 2019-2022 | |
| Abbott Laboratories | $75.54 | 2021-2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $70.88 | 2024 | Veozah |
| Alkermes, INC. | $67.11 | 2019-2023 | Vivitrol |
| Ironshore Pharmaceuticals INC. | $66.03 | 2019-2020 | |
| Grifols USA, LLC | $58.65 | 2019-2021 | |
| Pfizer INC. | $54.77 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $37.16 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $33.97 | 2019-2020 | |
| Glaxosmithkline, LLC. | $33.35 | 2020-2021 | |
| Abbvie INC. | $28.82 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.15 | 2021 | |
| Lilly USA, LLC | $16.81 | 2023 | Mounjaro |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13.43 | 2019 | |
| Sanofi Pasteur INC. | $13.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Fess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.